Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cosmos Health Inc. filings document the public-company record of a Nevada healthcare issuer with common stock listed on the Nasdaq Capital Market under COSM. Recent Form 8-K reports cover operating results, Regulation FD disclosures, Nasdaq minimum-bid-price compliance matters, board appointments, annual-meeting voting results and capital-structure proposals involving common stock and blank-check preferred stock.
The filing record also includes a Form 12b-25 notice for a delayed annual report and disclosures tied to business performance across contract manufacturing, wholesale distribution, proprietary nutraceutical brands and research and development. These documents address governance, listing status, share authorization, financial reporting timing and the company's operating subsidiaries and product portfolio.
Cosmos Health announced that its board has authorized a share repurchase program of up to $5 million of common stock. The company may buy back shares in the open market, through privately negotiated deals, or other permitted methods under SEC Rules 10b5-1 and 10b-18.
The program runs through December 31, 2026 and can be renewed at the company’s discretion, with actual purchases dependent on market conditions and other factors. CEO Greg Siokas said the plan reflects confidence in record revenue, improving margins, global expansion, and noted the program is almost half of market capitalization as of June 29, 2026.
Terzis Georgios reported open-market purchase transactions in this Form 4 filing.
Cosmos Health Inc. Chief Financial Officer Georgios Terzis acquired 168,135 shares of common stock at $0.2498 per share through a debt-for-equity exchange. Under a Debt Exchange Agreement dated June 16, 2026, $42,000 of debt the company owed to him was converted into these shares.
Following this transaction, Terzis directly holds 2,235,398 Cosmos Health common shares. The transaction reflects an insider increasing his equity stake while eliminating a portion of the company’s outstanding debt obligation to him at the fair market value as of June 16, 2026.
Siokas Grigorios reported open-market purchase transactions in this Form 4 filing.
Cosmos Health Inc. director and CEO Grigorios Siokas acquired additional common shares through a debt-for-equity exchange with the company. Under a Debt Exchange Agreement dated June 11, 2026, he received 218,447 shares of common stock at an Exchange Rate of $0.206 per share, equal to the fair market value on that date, in exchange for $45,000 of debt the company owed him. Following this transaction, he holds 13,481,808 common shares directly. This increases his equity stake while reducing a related-party debt obligation on the company’s balance sheet.
Siokas Grigorios reported open-market purchase transactions in this Form 4 filing.
Cosmos Health Inc. director and CEO Grigorios Siokas acquired additional common shares through a debt-for-equity exchange with the company. Under a Debt Exchange Agreement dated June 11, 2026, he received 218,447 shares of common stock at an Exchange Rate of $0.206 per share, equal to the fair market value on that date, in exchange for $45,000 of debt the company owed him. Following this transaction, he holds 13,481,808 common shares directly. This increases his equity stake while reducing a related-party debt obligation on the company’s balance sheet.
Siokas Grigorios reported open-market purchase transactions in this Form 4 filing.
Cosmos Health Inc. Chief Executive Officer Grigorios Siokas acquired 701,447 shares of common stock at $0.2281 per share. Instead of paying cash, the shares were received under a Debt Exchange Agreement dated June 10, 2026, in exchange for $160,000 of debt the company owed him.
Following this transaction, Mr. Siokas directly holds 13,263,361 shares of Cosmos Health common stock. The share price used in the exchange reflects the fair market value of the stock on June 10, 2026, as defined in the agreement.
Siokas Grigorios reported open-market purchase transactions in this Form 4 filing.
Cosmos Health Inc. Chief Executive Officer Grigorios Siokas acquired 701,447 shares of common stock at $0.2281 per share. Instead of paying cash, the shares were received under a Debt Exchange Agreement dated June 10, 2026, in exchange for $160,000 of debt the company owed him.
Following this transaction, Mr. Siokas directly holds 13,263,361 shares of Cosmos Health common stock. The share price used in the exchange reflects the fair market value of the stock on June 10, 2026, as defined in the agreement.
Cosmos Health Inc. director Karkantzos Theodoros Christos received an award of 20,000 shares of Common Stock at $0.283 per share under the company’s 2024 & 2025 Omnibus Incentive Plan. A related Restricted Stock Unit grant converted, leaving him with 35,000 common shares held directly after these compensation transactions, and no remaining RSUs.
Cosmos Health Inc. director Karkantzos Theodoros Christos received an award of 20,000 shares of Common Stock at $0.283 per share under the company’s 2024 & 2025 Omnibus Incentive Plan. A related Restricted Stock Unit grant converted, leaving him with 35,000 common shares held directly after these compensation transactions, and no remaining RSUs.
Cosmos Health Inc. director John James Hoidas received an award of 20,000 shares of common stock on May 19, 2026, converted from restricted stock units under the company’s 2024 & 2025 Omnibus Incentive Plan. The award was a compensation-related grant exempt under Rule 16b-3, bringing his direct holdings to 50,000 shares.
Cosmos Health Inc. director John James Hoidas received an award of 20,000 shares of common stock on May 19, 2026, converted from restricted stock units under the company’s 2024 & 2025 Omnibus Incentive Plan. The award was a compensation-related grant exempt under Rule 16b-3, bringing his direct holdings to 50,000 shares.
Cosmos Health Inc. director and secretary Demetrios G. Demetriades received an award of 20,000 shares of common stock at $0.283 per share as equity compensation. The grant came from the 2024 & 2025 Omnibus Incentive Plan, converting 20,000 vested RSUs into common shares and bringing his direct holdings to 55,000 shares.
Cosmos Health Inc. director and secretary Demetrios G. Demetriades received an award of 20,000 shares of common stock at $0.283 per share as equity compensation. The grant came from the 2024 & 2025 Omnibus Incentive Plan, converting 20,000 vested RSUs into common shares and bringing his direct holdings to 55,000 shares.
Cosmos Health Inc. director Aslidis Anastasios received an award of 40,000 shares of Common Stock on May 19, 2026, granted under the company’s 2024 & 2025 Omnibus Incentive Plan as equity compensation exempt under Rule 16b-3.
The award reflects the vesting and conversion of an equal number of Restricted Stock Units into common shares at a stated value of $0.283 per share. After these transactions, Anastasios directly holds 100,000 shares of Common Stock. The filing shows no open‑market purchases or sales, only compensation-related acquisitions.
Cosmos Health Inc. director Aslidis Anastasios received an award of 40,000 shares of Common Stock on May 19, 2026, granted under the company’s 2024 & 2025 Omnibus Incentive Plan as equity compensation exempt under Rule 16b-3.
The award reflects the vesting and conversion of an equal number of Restricted Stock Units into common shares at a stated value of $0.283 per share. After these transactions, Anastasios directly holds 100,000 shares of Common Stock. The filing shows no open‑market purchases or sales, only compensation-related acquisitions.
Cosmos Health Inc. director Suhel Bhutawala received an award of 20,000 shares of common stock valued at $0.283 per share on May 19, 2026 under the company’s 2024 & 2025 Omnibus Incentive Plan. These shares came from restricted stock units that vested immediately and were converted into common stock in transactions exempt under Rule 16b-3. Following the award and RSU conversion, Bhutawala directly holds 65,000 shares of Cosmos Health common stock.
Cosmos Health Inc. director Suhel Bhutawala received an award of 20,000 shares of common stock valued at $0.283 per share on May 19, 2026 under the company’s 2024 & 2025 Omnibus Incentive Plan. These shares came from restricted stock units that vested immediately and were converted into common stock in transactions exempt under Rule 16b-3. Following the award and RSU conversion, Bhutawala directly holds 65,000 shares of Cosmos Health common stock.
Cosmos Health Inc. Chief Financial Officer Georgios Terzis reported equity compensation involving 850,000 shares. He received an award of 850,000 shares of Common Stock at $0.283 per share, granted on May 19, 2026 under the company’s 2024 & 2025 Omnibus Incentive Plan and exempt under Rule 16b-3.
On the same date, 850,000 Restricted Stock Units converted into an equal number of Common Stock shares, with the RSUs vesting immediately at grant and then being fully settled. Following these transactions, Terzis holds 2,067,263 Common Stock shares directly.
Cosmos Health Inc. Chief Financial Officer Georgios Terzis reported equity compensation involving 850,000 shares. He received an award of 850,000 shares of Common Stock at $0.283 per share, granted on May 19, 2026 under the company’s 2024 & 2025 Omnibus Incentive Plan and exempt under Rule 16b-3.
On the same date, 850,000 Restricted Stock Units converted into an equal number of Common Stock shares, with the RSUs vesting immediately at grant and then being fully settled. Following these transactions, Terzis holds 2,067,263 Common Stock shares directly.